|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
US4215051A
(en)
|
1979-08-29 |
1980-07-29 |
Standard Oil Company (Indiana) |
Formation, purification and recovery of phthalic anhydride
|
|
US4713339A
(en)
|
1983-01-19 |
1987-12-15 |
Genentech, Inc. |
Polycistronic expression vector construction
|
|
US4757006A
(en)
|
1983-10-28 |
1988-07-12 |
Genetics Institute, Inc. |
Human factor VIII:C gene and recombinant methods for production
|
|
US4965199A
(en)
|
1984-04-20 |
1990-10-23 |
Genentech, Inc. |
Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4965188A
(en)
|
1986-08-22 |
1990-10-23 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
|
|
US5981216A
(en)
|
1985-04-01 |
1999-11-09 |
Alusuisse Holdings A.G. |
Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
|
|
JPH0788399B2
(ja)
|
1985-04-12 |
1995-09-27 |
ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド |
新規プロコアギュラント蛋白質
|
|
KR910006424B1
(ko)
|
1985-08-21 |
1991-08-24 |
인코텍스 비.브이 |
편성브리프(brief) 제조방법
|
|
WO1987004187A1
(en)
|
1986-01-03 |
1987-07-16 |
Genetics Institute, Inc. |
METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS
|
|
US5595886A
(en)
|
1986-01-27 |
1997-01-21 |
Chiron Corporation |
Protein complexes having Factor VIII:C activity and production thereof
|
|
US4800159A
(en)
|
1986-02-07 |
1989-01-24 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences
|
|
US5543502A
(en)
|
1986-06-24 |
1996-08-06 |
Novo Nordisk A/S |
Process for producing a coagulation active complex of factor VIII fragments
|
|
US4912040A
(en)
|
1986-11-14 |
1990-03-27 |
Genetics Institute, Inc. |
Eucaryotic expression system
|
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
|
CA1331157C
(en)
|
1987-04-06 |
1994-08-02 |
Randal J. Kaufman |
Method for producing factor viii:c-type proteins
|
|
US6060447A
(en)
|
1987-05-19 |
2000-05-09 |
Chiron Corporation |
Protein complexes having Factor VIII:C activity and production thereof
|
|
US6346513B1
(en)
|
1987-06-12 |
2002-02-12 |
Baxter Trading Gmbh |
Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
|
|
US5171844A
(en)
|
1987-06-12 |
1992-12-15 |
Gist-Brocades N.W. |
Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
|
|
DE3720246A1
(de)
|
1987-06-19 |
1988-12-29 |
Behringwerke Ag |
Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
|
|
FR2619314B1
(fr)
|
1987-08-11 |
1990-06-15 |
Transgene Sa |
Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
|
|
US4994371A
(en)
|
1987-08-28 |
1991-02-19 |
Davie Earl W |
DNA preparation of Christmas factor and use of DNA sequences
|
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
|
US5004803A
(en)
|
1988-11-14 |
1991-04-02 |
Genetics Institute, Inc. |
Production of procoagulant proteins
|
|
SE465222C5
(sv)
|
1989-12-15 |
1998-02-10 |
Pharmacia & Upjohn Ab |
Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
|
|
US5846951A
(en)
|
1991-06-06 |
1998-12-08 |
The School Of Pharmacy, University Of London |
Pharmaceutical compositions
|
|
MX9204374A
(es)
|
1991-07-25 |
1993-03-01 |
Idec Pharma Corp |
Anticuerpo recombinante y metodo para su produccion.
|
|
US6376463B1
(en)
|
1992-04-07 |
2002-04-23 |
Emory University |
Modified factor VIII
|
|
US5364771A
(en)
|
1992-04-07 |
1994-11-15 |
Emory University |
Hybrid human/porcine factor VIII
|
|
US5859204A
(en)
|
1992-04-07 |
1999-01-12 |
Emory University |
Modified factor VIII
|
|
US6037452A
(en)
|
1992-04-10 |
2000-03-14 |
Alpha Therapeutic Corporation |
Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
|
|
US5563045A
(en)
|
1992-11-13 |
1996-10-08 |
Genetics Institute, Inc. |
Chimeric procoagulant proteins
|
|
SE504074C2
(sv)
|
1993-07-05 |
1996-11-04 |
Pharmacia Ab |
Proteinberedning för subkutan, intramuskulär eller intradermal administrering
|
|
US5643575A
(en)
|
1993-10-27 |
1997-07-01 |
Enzon, Inc. |
Non-antigenic branched polymer conjugates
|
|
GB9422383D0
(en)
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
|
US6818439B1
(en)
|
1994-12-30 |
2004-11-16 |
Chiron Corporation |
Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
|
|
US6485726B1
(en)
|
1995-01-17 |
2002-11-26 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
|
US6030613A
(en)
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
|
US6086875A
(en)
|
1995-01-17 |
2000-07-11 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
SE9503380D0
(sv)
|
1995-09-29 |
1995-09-29 |
Pharmacia Ab |
Protein derivatives
|
|
US6458563B1
(en)
|
1996-06-26 |
2002-10-01 |
Emory University |
Modified factor VIII
|
|
WO1998005787A1
(en)
|
1996-08-02 |
1998-02-12 |
Bristol-Myers Squibb Company |
A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
CA2225189C
(en)
|
1997-03-06 |
2010-05-25 |
Queen's University At Kingston |
Canine factor viii gene, protein and methods of use
|
|
GB9722131D0
(en)
|
1997-10-20 |
1997-12-17 |
Medical Res Council |
Method
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
|
DE69937291T2
(de)
|
1998-04-02 |
2008-07-10 |
Genentech, Inc., South San Francisco |
Antikörpervarianten und fragmente davon
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
US20020142374A1
(en)
|
1998-08-17 |
2002-10-03 |
Michael Gallo |
Generation of modified molecules with increased serum half-lives
|
|
EP1006183A1
(en)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Recombinant soluble Fc receptors
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
KR101077001B1
(ko)
|
1999-01-15 |
2011-10-26 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
|
US7829085B2
(en)
|
1999-07-14 |
2010-11-09 |
Life Sciences Research Partners Vzw |
Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
|
|
JP2003530838A
(ja)
|
2000-04-12 |
2003-10-21 |
ヒューマン ゲノム サイエンシズ インコーポレイテッド |
アルブミン融合タンパク質
|
|
JP2003533537A
(ja)
|
2000-05-16 |
2003-11-11 |
リポクセン テクノロジーズ リミテッド |
タンパク質の誘導体化
|
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
|
CA2440582A1
(en)
|
2001-03-09 |
2002-10-03 |
Dyax Corp. |
Serum albumin binding moieties
|
|
KR101271635B1
(ko)
|
2001-12-21 |
2013-06-12 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
알부민 융합 단백질
|
|
US20080194481A1
(en)
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
|
ES2425738T3
(es)
|
2001-12-21 |
2013-10-17 |
Human Genome Sciences, Inc. |
Proteínas de fusión de la albúmina
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
CA2478011C
(en)
|
2002-03-01 |
2013-05-21 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
|
AU2002316574B2
(en)
|
2002-03-15 |
2008-05-01 |
Brandeis University |
Central airway administration for systemic delivery of therapeutics
|
|
US7425620B2
(en)
|
2002-08-14 |
2008-09-16 |
Scott Koenig |
FcγRIIB-specific antibodies and methods of use thereof
|
|
AU2003275103A1
(en)
|
2002-09-17 |
2004-04-08 |
Diffusion Science, Inc. |
Electrochemical generation, storage and reaction of hydrogen and oxygen using gas permeable catalyst-coated hollow microspheres
|
|
WO2004029207A2
(en)
|
2002-09-27 |
2004-04-08 |
Xencor Inc. |
Optimized fc variants and methods for their generation
|
|
DK1562972T3
(da)
|
2002-10-15 |
2010-12-06 |
Facet Biotech Corp |
Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
|
|
GB2395337B
(en)
|
2002-11-14 |
2005-12-28 |
Gary Michael Wilson |
Warning Unit
|
|
EP2368578A1
(en)
|
2003-01-09 |
2011-09-28 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
US7041635B2
(en)
|
2003-01-28 |
2006-05-09 |
In2Gen Co., Ltd. |
Factor VIII polypeptide
|
|
CA2788505C
(en)
|
2003-02-26 |
2018-09-04 |
Nektar Therapeutics |
Polymer-factor viii moiety conjugates
|
|
KR100851263B1
(ko)
|
2003-02-28 |
2008-08-08 |
가부시키가이샤 구라레 |
경화성 수지 조성물
|
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
PT1624891E
(pt)
|
2003-05-06 |
2010-01-05 |
Syntonix Pharmaceuticals Inc |
Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
|
|
US7348004B2
(en)
|
2003-05-06 |
2008-03-25 |
Syntonix Pharmaceuticals, Inc. |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
KR101113726B1
(ko)
|
2003-08-12 |
2012-02-27 |
리폭센 테크놀로지즈 리미티드 |
단백질 유도 및 컨쥬게이션용 시알산 유도체
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
US7211559B2
(en)
|
2003-10-31 |
2007-05-01 |
University Of Maryland, Baltimore |
Factor VIII compositions and methods
|
|
CA2545603A1
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
|
|
WO2005077981A2
(en)
|
2003-12-22 |
2005-08-25 |
Xencor, Inc. |
Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
|
|
EP1706424B1
(en)
|
2004-01-12 |
2009-07-22 |
Applied Molecular Evolution, Inc. |
Fc region variants
|
|
US7276585B2
(en)
|
2004-03-24 |
2007-10-02 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
|
CN103172731A
(zh)
|
2004-07-15 |
2013-06-26 |
赞科股份有限公司 |
优化的Fc变体
|
|
US7566701B2
(en)
|
2004-09-07 |
2009-07-28 |
Archemix Corp. |
Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
|
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
|
DK1835938T3
(da)
*
|
2004-12-27 |
2013-11-04 |
Baxter Int |
Polymer-von Willebrand-faktor-konjugater
|
|
AU2006280312A1
(en)
|
2005-08-12 |
2007-02-22 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US7846445B2
(en)
*
|
2005-09-27 |
2010-12-07 |
Amunix Operating, Inc. |
Methods for production of unstructured recombinant polymers and uses thereof
|
|
EP2863222A1
(en)
|
2006-03-06 |
2015-04-22 |
Amunix Operating Inc. |
Unstructured recombinant polymers and uses thereof
|
|
PL2032607T5
(pl)
|
2006-06-14 |
2017-10-31 |
Csl Behring Gmbh |
Rozszczepialne proteolitycznie białko fuzyjne obejmujące czynnik krzepnięcia krwi
|
|
US9187532B2
(en)
|
2006-07-21 |
2015-11-17 |
Novo Nordisk A/S |
Glycosylation of peptides via O-linked glycosylation sequences
|
|
AU2007294805A1
(en)
|
2006-09-14 |
2008-03-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US20100075375A1
(en)
|
2006-10-03 |
2010-03-25 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates
|
|
CA2665480C
(en)
|
2006-10-04 |
2019-11-12 |
Novo Nordisk A/S |
Glycerol linked pegylated sugars and glycopeptides
|
|
US8754194B2
(en)
*
|
2006-12-22 |
2014-06-17 |
Csl Behring Gmbh |
Modified coagulation factors with prolonged in vivo half-life
|
|
EP1935430A1
(en)
|
2006-12-22 |
2008-06-25 |
CSL Behring GmbH |
Modified coagulation factors with prolonged in vivo half-life
|
|
HRP20110368T1
(hr)
|
2007-06-21 |
2011-06-30 |
Technische Universitt Mnchen |
Biološki aktivni proteini s povećanom stabilnošću in vivo i/ili in vitro
|
|
CN103298935A
(zh)
|
2007-08-15 |
2013-09-11 |
阿穆尼克斯公司 |
用于改善生物活性多肽性能的组合物和方法
|
|
EP2209908B1
(en)
|
2007-11-01 |
2014-09-03 |
University Of Rochester |
Recombinant factor viii having increased stability
|
|
AU2008323768A1
(en)
*
|
2007-11-09 |
2009-05-14 |
Baxter Healthcare S.A. |
Modified recombinant Factor VIII and von Willebrand Factor and methods of use
|
|
TW201731488A
(zh)
|
2007-12-28 |
2017-09-16 |
巴克斯歐塔公司 |
重組ｖｗｆ調配物
|
|
DK2865760T3
(en)
*
|
2008-06-24 |
2018-01-15 |
Csl Behring Gmbh |
Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
|
|
JP2012510060A
(ja)
|
2008-11-24 |
2012-04-26 |
バイエル・ヘルスケア・エルエルシー |
シリカをベースとする活性化部分トロンボプラスチン時間アッセイにおけるｐｅｇ化血液凝固因子の活性の測定方法
|
|
SI2393828T1
(sl)
*
|
2009-02-03 |
2017-01-31 |
Amunix Operating Inc. |
Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
|
|
US20110046060A1
(en)
|
2009-08-24 |
2011-02-24 |
Amunix Operating, Inc., |
Coagulation factor IX compositions and methods of making and using same
|
|
US8680050B2
(en)
|
2009-02-03 |
2014-03-25 |
Amunix Operating Inc. |
Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
|
|
US8703717B2
(en)
|
2009-02-03 |
2014-04-22 |
Amunix Operating Inc. |
Growth hormone polypeptides and methods of making and using same
|
|
WO2010118435A2
(en)
|
2009-04-10 |
2010-10-14 |
Tufts Medical Center, Inc. |
Par-1 activation by metalloproteinase-1 (mmp-1)
|
|
JP5805634B2
(ja)
|
2009-06-08 |
2015-11-04 |
アムニクス オペレーティング インコーポレイテッド |
成長ホルモンポリペプチド並びにその作成及び使用方法
|
|
AU2010258898B8
(en)
|
2009-06-08 |
2015-02-05 |
Amunix Operating Inc. |
Glucose-regulating polypeptides and methods of making and using same
|
|
AU2010284977A1
(en)
|
2009-08-20 |
2012-03-29 |
Csl Behring Gmbh |
Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
|
|
WO2011028344A2
(en)
|
2009-08-25 |
2011-03-10 |
Amunix Operating Inc. |
Interleukin-1 receptor antagonist compositions and methods of making and using same
|
|
HUE029454T2
(en)
|
2009-11-13 |
2017-03-28 |
Grifols Therapeutics Inc |
Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
|
|
BR112012013502A2
(pt)
*
|
2009-12-06 |
2017-01-10 |
Biogen Idec Hemophilia Inc |
"polipeptídeos quiméricos e híbridos de fator viii-fc, e métodos de uso dos mesmos".
|
|
EP2536754A1
(en)
|
2010-02-16 |
2012-12-26 |
Novo Nordisk A/S |
Factor viii fusion protein
|
|
WO2011101242A1
(en)
*
|
2010-02-16 |
2011-08-25 |
Novo Nordisk A/S |
Factor viii molecules with reduced vwf binding
|
|
JP6148979B2
(ja)
|
2010-05-20 |
2017-06-14 |
アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ |
分解性クロストリジウム毒素
|
|
ES2739503T3
(es)
|
2010-07-09 |
2020-01-31 |
Bioverativ Therapeutics Inc |
Moléculas de cadena simple procesables y polipéptidos producidos usándolas
|
|
US9611310B2
(en)
|
2010-07-09 |
2017-04-04 |
Bioverativ Therapeutics Inc. |
Systems for factor VIII processing and methods thereof
|
|
US20130017997A1
(en)
|
2010-08-19 |
2013-01-17 |
Amunix Operating Inc. |
Factor VIII Compositions and Methods of Making and Using Same
|
|
CN111499761A
(zh)
*
|
2012-01-12 |
2020-08-07 |
比奥贝拉蒂治疗公司 |
嵌合因子viii多肽及其用途
|
|
CN111548418A
(zh)
|
2012-02-15 |
2020-08-18 |
比奥贝拉蒂治疗公司 |
因子viii组合物及其制备和使用方法
|
|
NZ628014A
(en)
|
2012-02-15 |
2016-09-30 |
Biogen Ma Inc |
Recombinant factor viii proteins
|
|
AU2013290173B2
(en)
|
2012-07-11 |
2018-02-15 |
Bioverativ Therapeutics Inc. |
Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
|
|
EP3013359A4
(en)
|
2013-06-28 |
2017-01-25 |
Biogen MA Inc. |
Thrombin cleavable linker
|
|
HK1223302A1
(zh)
|
2013-06-28 |
2017-07-28 |
Bioverativ Therapeutics Inc. |
具有xten的凝血酶可裂解连接子和其用途
|
|
PH12016501323B1
(en)
*
|
2014-01-10 |
2022-04-29 |
Bioverativ Therapeutics Inc |
Factor viii chimeric proteins and uses thereof
|
|
JP7763589B2
(ja)
*
|
2018-05-18 |
2025-11-04 |
バイオベラティブ セラピューティクス インコーポレイテッド |
血友病ａを処置する方法
|